PARK CIRCLE Co Acquires New Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

PARK CIRCLE Co acquired a new stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,916 shares of the company’s stock, valued at approximately $237,000.

A number of other hedge funds have also added to or reduced their stakes in GEHC. Meitav Investment House Ltd. bought a new stake in shares of GE HealthCare Technologies during the second quarter worth $113,000. Center for Financial Planning Inc. bought a new stake in shares of GE HealthCare Technologies during the second quarter worth $26,000. Aspire Private Capital LLC bought a new stake in shares of GE HealthCare Technologies during the second quarter worth $26,000. Larson Financial Group LLC bought a new stake in shares of GE HealthCare Technologies during the second quarter worth $27,000. Finally, Sanctuary Wealth Management L.L.C. bought a new stake in shares of GE HealthCare Technologies during the second quarter worth $28,000. 79.18% of the stock is owned by institutional investors.

GE HealthCare Technologies Stock Up 0.2 %

Shares of NASDAQ GEHC traded up $0.11 during trading on Monday, hitting $73.11. 739,688 shares of the company traded hands, compared to its average volume of 3,021,254. The business’s fifty day moving average is $67.31 and its 200 day moving average is $73.26. GE HealthCare Technologies Inc. has a fifty-two week low of $53.00 and a fifty-two week high of $87.83. The firm has a market capitalization of $33.28 billion and a price-to-earnings ratio of 21.73. The company has a debt-to-equity ratio of 1.44, a quick ratio of 0.97 and a current ratio of 1.25.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Tuesday, October 31st. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.10. GE HealthCare Technologies had a net margin of 8.91% and a return on equity of 24.46%. The firm had revenue of $4.82 billion for the quarter, compared to analyst estimates of $4.80 billion. During the same quarter in the prior year, the business earned $0.87 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Equities research analysts predict that GE HealthCare Technologies Inc. will post 3.81 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 20th were issued a dividend of $0.03 per share. The ex-dividend date was Thursday, October 19th. This represents a $0.12 annualized dividend and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio is currently 3.57%.

Wall Street Analyst Weigh In

GEHC has been the topic of a number of recent research reports. Wells Fargo & Company initiated coverage on shares of GE HealthCare Technologies in a report on Wednesday, August 16th. They set an “overweight” rating and a $90.00 price target on the stock. Argus initiated coverage on shares of GE HealthCare Technologies in a report on Friday, August 25th. They set a “buy” rating and a $80.00 price target on the stock. Bank of America initiated coverage on shares of GE HealthCare Technologies in a report on Monday, July 31st. They set a “neutral” rating and a $82.00 price target on the stock. Finally, Citigroup initiated coverage on shares of GE HealthCare Technologies in a report on Tuesday, September 19th. They set a “buy” rating and a $82.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.44.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.